

Pseudovitamin B₁₂ Is the Predominant Cobamide of an Algal Health Food, Spirulina Tablets

Fumio Watanabe,^{*,†} Hiromi Katsura,[†] Shigeo Takenaka,[‡] Tomoyuki Fujita,[§] Katsuo Abe,[†]
Yoshiyuki Tamura,[‡] Toshiyuki Nakatsuka,[⊥] and Yoshihisa Nakano[§]

Department of Health Science, Kochi Women's University, Kochi 780-8515, Japan;
Laboratory of Nutrition and Food Science, Haboromo-gakuen College, Sakai 592-8344, Japan;
Department of Applied Biological Chemistry, Osaka Prefecture University, Sakai 599-8531, Japan; and
Department of Food Science, Shimane Women's College, Matsue 690-0044, Japan

The vitamin B₁₂ concentration of an algal health food, spirulina (*Spirulina* sp.) tablets, was determined by both *Lactobacillus leichmannii* ATCC 7830 microbiological and intrinsic factor chemiluminescence methods. The values determined with the microbiological method were ~6–9-fold greater in the spirulina tablets than the values determined with the chemiluminescence method. Although most of the vitamin B₁₂ determined with the microbiological method was derived from various vitamin B₁₂ substitutive compounds and/or inactive vitamin B₁₂ analogues, the spirulina contained a small amount of vitamin B₁₂ active in the binding of the intrinsic factor. Two intrinsic factor active vitamin B₁₂ analogues (major and minor) were purified from the spirulina tablets and partially characterized. The major (83%) and minor (17%) analogues were identified as pseudovitamin B₁₂ and vitamin B₁₂, respectively, as judged from data of TLC, reversed-phase HPLC, ¹H NMR spectroscopy, ultraviolet–visible spectroscopy, and biological activity using *L. leichmannii* as a test organism and the binding of vitamin B₁₂ to the intrinsic factor.

Keywords: Vitamin B₁₂; pseudovitamin B₁₂; algal health food; spirulina tablet; intrinsic factor; *Lactobacillus leichmannii*

INTRODUCTION

A health food fad involves tablets of *Spirulina* sp., blue-green algae. Many preclinical studies suggest that *Spirulina* cells have therapeutic properties such as hepatoprotective (Vadiraja et al., 1998), immunological (Yang et al., 1997), and antiviral (Hayashi et al., 1996) activities. Spirulina (*Spirulina* sp.) tablets also contain large amounts of vitamin B₁₂ (B₁₂ or CN-B₁₂) and can contribute to human B₁₂ needs, especially for vegetarians. Herbert and Drivas (1982), however, have reported that most of the B₁₂ compounds found in the spirulina tablets are biologically inactive B₁₂ analogues, probably cobinamide (α -ligand-free B₁₂)-like compounds. Several studies (Dagnelie et al., 1991; Herbert and Drivas, 1982; van den Berg et al., 1988) have shown that spirulina B₁₂ may not be bioavailable in mammals. Dagnelie et al. (1991) have also reported that inclusion of spirulina in B₁₂-deficient children's diet results in a further deterioration of mean corpuscular volume despite an increase in B₁₂ plasma level, suggesting that spirulina contains some compounds interfering with B₁₂ metabolism and/or biologically inactive B₁₂ analogues. Although an extract of spirulina tablets has been reported to contain B₁₂ analogues that can block B₁₂ metabolism (Herbert, 1988), there is no information available on

details of the spirulina B₁₂ analogues. If the spirulina B₁₂ analogues are analyzed in details and then identified, their bioavailability and/or toxicity will be shown more clearly.

In the present paper, we subject three brands of the spirulina tablets to both *Lactobacillus leichmannii* ATCC 7830 microbiological B₁₂ assay method and chemiluminescence B₁₂ analyzer using hog intrinsic factor (IF), the most specific B₁₂-binding protein. We also describe the purification and characterization of two B₁₂ analogues active in the binding of IF from the spirulina tablets and discuss the bioavailability of the analogues in mammals.

MATERIALS AND METHODS

Materials. Cyano-B₁₂ (CN-B₁₂) and a reversed-phase high-pressure liquid chromatography (HPLC) column (Wakosil-II 5C18RS, \varnothing 4.6 \times 150 mm; particle size = 5 μ m) were obtained from Wako Pure Chemical Industries (Osaka, Japan). A filter paper (type 50) for chromatography was obtained from Toyo Roshi (Tokyo, Japan). A B₁₂ assay medium for *L. leichmannii* was obtained from Nissui (Tokyo, Japan). Silica gel 60 thin-layer chromatography (TLC) aluminum sheets were obtained from Merck (Darmstadt, Germany). Amberlite XAD-4 was obtained from Japan Organo Co. (Tokyo, Japan). Sephadex G-15 was purchased from Pharmacia-LKB Biotechnology (Uppsala, Sweden). Cosmosil 140C18-OPN was obtained from Nacalai Tesque Inc. (Kyoto, Japan). Cyanocobamides (5-hydroxybenzimidazolylcobamide, benzimidazolylcobamide, *p*-cresolylcobamide, and pseudovitamin B₁₂) isolated from bacteria were kindly provided by Dr. E. Stupperich, Ulm University, Germany. All other reagents used were of the highest purity commercially available. The spirulina tablets tested were purchased from a local market in Kochi-city, Japan.

* Author to whom correspondence should be addressed (telephone and fax +81-88-873-2483; e-mail watanabe@cc.kochi-wu.ac.jp).

[†] Kochi Women's University.

[‡] Haboromo-gakuen College.

[§] Osaka Prefecture University.

[⊥] Shimane Women's College.

A Hitachi (Tokyo, Japan) spectrophotometer (U-1000) and a Shimadzu (Kyoto, Japan) UV-visible spectrophotometer (UV-1600) were used for measuring the turbidity of *L. leichmannii* test culture in the microbiological method and the absorbance of CN-B₁₂ and its analogues in paper chromatography, respectively. A fully automated chemiluminescence B₁₂ analyzer ACS 180 (Chiron Diagnostics, East Walpole, MA) was used for B₁₂ assay.

Assay of Vitamin B₁₂. B₁₂ was assayed according to the microbiological method with *L. leichmannii* ATCC 7830 and a B₁₂ assay medium (Nissui, Tokyo, Japan) and by the fully automated chemiluminescence B₁₂ analyzer ACS 180 (Chiron Diagnostics) according to the manufacturer's instructions. B₁₂ extracts were directly applied to the chemiluminescence B₁₂ analyzer. They were diluted with distilled water up to a B₁₂ concentration range of 0.01–0.2 µg/L and used as samples for the microbiological method. The turbidity (%T) of *L. leichmannii* test culture was measured at 600 nm with a Hitachi spectrophotometer (U-1000).

Extraction of Vitamin B₁₂ in Spirulina Tablets. Each (1 g) of the spirulina tablets was powdered by the use of a food mill (MX-X51, National, Osaka, Japan) and added to 50 mL of 0.05 mol/L acetate buffer, pH 4.8. Total B₁₂ was extracted from the cell suspension by boiling with KCN at acidic pH (Frenkel et al., 1980); specifically, 20 mg of KCN was added to the suspension, which was boiled for 30 min at 98 °C in a glass flask capped with aluminum foil under dark conditions. The extraction procedures were done in a Dalton (Tokyo, Japan) draft chamber. The extract was centrifuged at 10000g for 10 min. The supernatant was used for the B₁₂ assay.

Paper Chromatography. The extract of the spirulina tablets was spotted quantitatively (4000 pg for the chemiluminescence method) on the filter paper (type 50) and developed with 1-butanol/2-propanol/water (10:7:10) as a solvent in the dark at room temperature. The filter paper was dried and cut into small pieces (5 mm) by scissors. B₁₂ was extracted with 1 mL of distilled water from the pieces of the filter paper for 24 h at 4 °C in the dark and used as samples. Authentic CN-B₁₂ (40 µg) was analyzed under the same conditions, extracted from the filter papers, and determined with a Shimadzu UV-visible spectrophotometer (UV-1600) by measuring absorbance at 361 nm.

Sephadex G-15 Gel Filtration. The extract of the spirulina tablet was put on a column (25 × 50 mm) of Amberlite XAD-4 equilibrated with 1% (v/v) acetic acid solution and washed with 200 mL of the same solution. The spirulina B₁₂ analogues were eluted with 150 mL of 80% (v/v) ethanol solution, evaporated to dryness under reduced pressure, and dissolved in 2 mL of distilled water. This solution was put on a column (14 × 900 mm) of Sephadex G-15 equilibrated with 0.1 mol/L NaCl solution and eluted with the same solution. The column eluate was collected at 2 mL with a Bio-Rad Laboratories (Richmond, CA) fraction collector (Model 2110). B₁₂ was assayed in the fractions by both microbiological and chemiluminescence methods. All procedures were done in the dark.

Purification of Vitamin B₁₂ Analogues from Spirulina Tablets. Four hundred grams of the spirulina tablets was powdered by the use of the food mill and added to 4 L of 0.063 mol/L acetate buffer, pH 4.8. KCN was added to the cell suspension at the final concentration of 10 mmol/L. Total B₁₂ was extracted for 30 min at 98 °C from the cell suspension in a loosely capped container. Amberlite XAD-4 resin (1 kg), which was washed with 10 L of methanol and equilibrated with distilled water, was added to the supernatant fraction of the boiled cell suspension centrifuged at 10000g for 10 min and stirred for 3 h at room temperature in the dark. The resin suspension was passed through a glass funnel with frittered disk (type 25G1, Iwaki, Tokyo, Japan), and the resin was washed with 5 L of distilled water. The washed resin was added to 2 L of an 80% (v/v) methanol solution and stirred for 3 h at room temperature in the dark. The resin suspension was passed through the glass funnel. The eluant containing B₁₂ analogues was pooled, evaporated to dryness under reduced pressure, and dissolved in 30 mL of distilled water.

The solution was put on a column (24 × 70 mm) of Cosmosil 140C18-OPN (Nacalai Tesque, Inc.), which was washed with 75% (v/v) ethanol solution and equilibrated with distilled water, and eluted with a linear gradient of 0–25% (v/v) ethanol. The B₁₂-active fractions were assayed by the chemiluminescence B₁₂ analyzer, pooled, evaporated to dryness under reduced pressure, and dissolved with a small amount of distilled water. The solution was further twice purified with the Cosmosil column chromatography under the same conditions. The concentrated solution was purified by HPLC using a Shimadzu HPLC apparatus (LC-6A pump, SPD-6A spectrophotometer, CTO-6A column oven, C-R6A Chromatopac). The sample (100 µL) was put on a reversed-phase HPLC column (Wakosil-II 5C18RS, Ø 4.6 × 150 mm; particle size = 5 µm) equilibrated with a 20% (v/v) methanol solution containing 1% (v/v) acetic acid at 35 °C. The flow rate was 1 mL/min. The spirulina B₁₂ analogues were isocratically eluted with the same solution, monitored by measuring absorbance at 278 nm, and collected at 1 mL with a Bio-Rad Laboratories fraction collector (Model 2110). The B₁₂-active fractions were pooled, evaporated to dryness under reduced pressure, and dissolved in a small amount of distilled water. The concentrated solution was put on a silica gel 60 TLC sheet and developed with 1-butanol/2-propanol/water (10:7:10 v/v) as a solvent in the dark at room temperature. Two red spots were separated by the TLC, collected, extracted with the solvent, evaporated to dryness under reduced pressure, and dissolved in 50 µL of distilled water. Each concentrated solution was further purified with the TLC under the same conditions. Each final red spot was re-extracted with the solvent and dissolved in 20 µL of distilled water. Each concentrated solution was further purified with the reversed-phased HPLC under the same conditions. Each final red fraction was collected, evaporated to dryness under reduced pressure, dissolved in 0.5 mL of distilled water, and used as a purified spirulina B₁₂ analogue. The B₁₂ analogues were purified from total amounts of 2 kg of the spirulina tablets.

Analytical TLC and HPLC. The concentrated solutions (2 µL) of the purified spirulina B₁₂ analogues, CN-B₁₂, and cyanocobamides (benzimidazolyl, 5-hydroxybenzimidazolyl, *p*-cresolyl cyanocobamides, and pseudovitamin B₁₂) were spotted on the silica gel 60 TLC sheets and developed with 1-butanol/2-propanol/water (10:7:10 v/v) and 2-propanol/NH₄OH (28%)/water (7:1:2 v/v) as solvents in the dark at room temperature. The TLC sheets were dried, and *R_f* values of the red spots of the corrinoids were determined.

In the case of HPLC, the concentrated solutions (2 µL) of the purified spirulina B₁₂ analogues, CN-B₁₂, and these cyanocobamides were analyzed with the reversed-phase HPLC column (Wakosil-II 5C18RS, Ø 4.6 × 150 mm; particle size = 5 µm). The corrinoids were eluted with a 20% (v/v) methanol solution containing 1% (v/v) acetic acid and with a linear gradient of 5–70% (v/v) methanol in 1% (v/v) acetic acid solution at 35 °C and monitored by measuring the absorbance at 278 nm. The flow rate was 1 mL/min.

Ultraviolet-Visible Spectra. The spectra were measured with a Shimadzu spectrophotometer (UV-1600) at room temperature. Quartz cuvettes (*d* = 1 cm) were used. The purified spirulina B₁₂ analogues were dissolved in 1 mL of CH₃OH. The ultraviolet-visible spectrum of the purified compound I (28.4 µmol/L) had λ_{max} (absorbance) at 545.5 (0.236), 517.5 (0.234), 409 (0.127), 360 (0.789), 321 (0.282), and 277 (0.521) nm. That of the purified compound II (5.2 µmol/L) had λ_{max} (absorbance) at 549.5 (0.045), 520 (0.04), 361 (0.153), 322 (0.059), and 278.5 (0.100) nm.

¹H NMR Spectra. ¹H NMR spectra were measured with a JEOL JNM α-500 spectrometer in D₂O. Chemical shifts were given on as δ (ppm) with 3-(trimethylsilyl)propionic acid-*d*₄ sodium salt (TSP) as an internal standard. ¹H NMR spectral data of the compound I: δ 8.13 (1H, s), 7.20 (1H, s), 6.53 (1H, *J* = 3.7 Hz), 6.08 (1H, s), 2.56 (3H, s), 2.44 (3H, s), 1.79 (3H, s), 1.50 (3H, s), 1.41 (3H, s), 1.37 (3H, s), 1.25 (3H, *J* = 6.4 Hz), 1.18 (3H, s), 0.45 (3H, s). ¹H NMR spectral data of compound II: δ 7.28 (1H, s), 7.09 (1H, s), 6.51 (1H, s), 6.35 (1H, d, *J* = 3.5 Hz), 6.09 (1H, s), 2.57 (3H, s), 2.54 (3H, s),

Table 1. Vitamin B₁₂ Concentration of Spirulina Tablets

	vitamin B ₁₂ concn ^a (μg/100 g of dry wt)		
	claim on bottle ^b	microbiological assay	chemiluminescence assay
A	233	244.3 ± 3.3	8.3 ± 0.1
B	100–250	127.2 ± 6.6	6.2 ± 0.1
C	none	147.5 ± 19.3	17.4 ± 0.2

^a All values obtained represent mean ± SEM (*n* = 4). The detailed procedures were described in the text. ^b Determined by microbiological assay.




Figure 1. Paper chromatographic analysis of vitamin B₁₂ of spirulina tablets. Migration patterns of authentic CN-B₁₂ (A) and spirulina B₁₂ were determined according to microbiological (B) and chemiluminescence methods (C). Data present a typical migration pattern of B₁₂ on paper chromatography from three experiments.

2.26 (6H, s), 1.87 (3H, s), 1.45 (3H, s), 1.40 (3H, s), 1.39 (3H, s), 1.25 (3H, d, *J* = 6.1 Hz), 1.20 (3H, s), 0.45 (3H, s).

RESULTS

Vitamin B₁₂ Contents Determined with the Microbiological Method and IF Chemiluminescence B₁₂ Analyzer in Spirulina Tablets. Table 1 shows the B₁₂ contents determined with the two methods in the algal tablets. The values determined by using the microbiological method are significantly different from those determined by using the chemiluminescence method in three spirulina tablets (A–C). Remarkably,




Figure 2. Elution profile of spirulina vitamin B₁₂ during Sephadex G-15 gel filtration: (A) absorbance peaks at 278 nm during Sephadex G-15 of spirulina B₁₂ partially purified by Amberlite XAD-4; (B) amount of spirulina B₁₂ determined by using the microbiological (□) and chemiluminescence methods (■) in the fractions I–V. Data present a typical elution pattern of B₁₂ on the column chromatography from three experiments.

in all spirulina tablets, B₁₂ contents determined with the microbiological method were ~6–9-fold greater than the values determined with the chemiluminescence method.

Paper and Sephadex G-15 Chromatography of a Vitamin B₁₂ Extract of the Spirulina Tablets. To clarify why there are such differences between the values determined with the two methods in the spirulina tablets, an extract of the spirulina tablets was analyzed by paper chromatography. Authentic CN-B₁₂ gave a single red spot with an *R_f* of 0.5 (Figure 1). The spirulina B₁₂ was separated as about three peaks with *R_f* values of 0.33 (17.4%), 0.53 (52.3%), and 0.75 (30.3%) with the microbiological method but as two peaks of *R_f* values of 0.35 (31.2%) and 0.53 (35.2%) with the chemiluminescence method. Only a few percentage points of the sum of B₁₂ determined with the microbiological method was recovered in the B₁₂-active fractions with *R_f* values of 0.35 and 0.53 by using the chemiluminescence method. *R_f* values of authentic cyanocobamides, pseudo-B₁₂ and 5-hydroxybenzimidazolyl, benzimidazolyl, and *p*-cresolyl cyanocobamides, were 0.34, 0.40, 0.42, and 0.68, respectively.

After B₁₂ was partially purified from the extract of the spirulina tablets by an Amberlite XAD-4 column chromatography, the partially purified B₁₂ was analyzed with Sephadex G-15 column chromatography (Figure 2). B₁₂ was detected in fraction III (authentic CN-B₁₂ fraction) with the chemiluminescence method but in fractions I–IV with the microbiological method. These results indicate that in the spirulina tablets, most of the B₁₂ determined by using the microbiological method




Figure 3. Silica gel 60 TLC pattern of the purified spirulina B₁₂ analogues. Each final purified preparation (2 μ L) was spotted on the silica gel 60 TLC sheet and developed with 2-propanol/NH₄OH (28%)/water (7: 1: 2 v/v) at room temperature in the dark. Data present a typical migration pattern of the purified B₁₂ analogues on the TLC from three experiments.

was derived from various B₁₂ substitutive compounds and/or B₁₂ analogues inactive for the binding of IF.

Purification of Vitamin B₁₂ Analogues Active in the Binding of IF from the Spirulina Tablets. The IF-active B₁₂ analogues were purified from the extract of the spirulina tablets. The B₁₂ analogues were separated as two (major and minor) red spots by the preparative TLC. Analytical silica gel 60 TLC and C₁₈ reversed-phase HPLC for the final preparation of the major compound **I** and minor compound **II** gave a single red spot with *R_f* values of 0.42 and 0.56, respectively (Figure 3), and a single peak with a retention times of 12.8 and 15.6 min, respectively. These results indicate that the B₁₂ analogues, compounds **I** and **II**, are purified to homogeneity.

Characterization of the Purified Spirulina Vitamin B₁₂ Analogues. The ultraviolet–visible spectrum of each purified compound **I** and **II** showed a typical absorption spectrum of cobalt-containing corrinoids. The purified spirulina B₁₂ analogues, authentic CN-B₁₂, and cyanocobamides (pseudo-B₁₂ and 5-hydroxybenzimidazolyl, benzimidazolyl, and *p*-cresolyl cyanocobamides), which occur in bacteria, were analyzed by using analytical silica gel 60 TLC and C₁₈ reversed-phase HPLC (Table 2). The *R_f* values (0.14 and 0.42 in solvents I and II, respectively, by TLC) of compound **I** were identical to the values of pseudo-B₁₂, of which the retention times (12.8 and 18.4 min with the isocratic and gradient elution, respectively, by HPLC) were also identical to those of compound **I**. The *R_f* values (0.23 and 0.56) of compound **II** were identical to the values

of authentic CN-B₁₂, of which the retention times (15.6 and 19.0 min) were also identical to those of compound **II**.

In the ¹H NMR spectrum of compound **I**, two protons (δ 8.13 and 7.20) due to adenyl moiety, one anomeric proton [δ 6.53 (d, *J* = 3.7 Hz)] of ribose, and an olefinic proton (δ 6.08, H-10) were observed in the low-field region. These data suggest the presence of the adenyl and ribosyl moieties in compound **I**. Eight singlet methyl signals at δ 0.45, 1.18, 1.37, 1.41, 1.50, 1.79, 2.44, and 2.56 derived from the corrin skeleton and one doublet methyl signal at δ 1.25 (d, *J* = 6.4 Hz) on the propyl moiety were also observed in the high-field region. These spectral data were identified with those of pseudo-B₁₂ cited in the literature (Stupperich and Kräutler, 1988). Therefore, compound **I** was identified as pseudo-B₁₂. On the other hand, compound **II** was identified as B₁₂, as the ¹H NMR spectrum of compound **II** completely agreed with that of authentic CN-B₁₂.

L. leichmannii ATCC 7830 could utilize both pseudo-B₁₂ and compound **I** as well as authentic CN-B₁₂ (Table 3). Although both pseudo-B₁₂ and compound **I** showed only ~32–36% of the activity of authentic CN-B₁₂ in the IF chemiluminescence assay method, the relative amount of compound **II** was identical to that of CN-B₁₂ in both B₁₂ assay methods. These results indicate that the purified spirulina B₁₂ analogues, compounds **I** and **II**, are pseudo-B₁₂ and B₁₂, respectively.

DISCUSSION

B₁₂ contents of foods have been determined by bioassay with B₁₂-requiring microorganisms; *L. leichmannii* ATCC7830 has been used widely. Herbert and Drivas (1982) have reported that in some spirulina tablets >80% of the B₁₂ determined with the microbiological method is B₁₂ analogues (cobinamide-like compounds), which cannot be assayed by a radioisotope dilution assay method with hog IF. The B₁₂ contents determined by using the *L. leichmannii* microbiological method have been also shown to be 8-fold greater than the values determined with the radioisotope dilution assay method (van den Berg et al., 1988) or the chemiluminescence method (Watanabe et al., 1998). Our previous study (Watanabe et al., 1998) has indicated that except for foods containing substantial amounts of inactive B₁₂ and/or B₁₂ substitutive compounds, the observed correlation coefficient between the microbiological and chemiluminescence methods in foods is excellent. These observations support our results in Table 1.

It has been reported that *L. leichmannii* ATCC 7830 can utilize the B₁₂ analogues inactive for human as well as B₁₂, but not cobinamide, and that both deoxyribosides and deoxynucleotides may substitute B₁₂ (Schneider, 1987). Both the findings reported by Herbert and Drivas

Table 2. *R_f* Values and Retention Times of the Purified Spirulina B₁₂ Analogues, CN-B₁₂, and Cyanocobamides on TLC and HPLC


	spirulina compound I	spirulina compound II	B ₁₂	benzimidazolyl cobamide	5-hydroxybenzimidazolyl cobamide	pseudovitamin B ₁₂	<i>p</i> -cresolyl cobamide
silica gel 60 TLC ^a							
solvent I	0.14	0.23	0.23	0.18	0.20	0.14	0.38
solvent II	0.42	0.56	0.56	0.52	0.47	0.42	0.62
C ₁₈ reversed-phase HPLC ^b							
isocratic	12.8	15.6	15.6	12.2	11.8	12.8	>30
gradient	18.4	19.0	19.0	18.3	18.2	18.4	26.1

^a Solvent I, 1-butanol/2-propanol/water (10:7:10); solvent II, 2-propanol/NH₄OH (28%)/water (7: 1: 2). ^b Isocratic, 20% (v/v) methanol solution containing 1% (v/v) acetic acid; gradient, a linear gradient of methanol (5–70%, v/v) in 1% (v/v) acetic acid solution.

Table 3. Biological Activities of the Purified Spirulina B₁₂ Analogues in the B₁₂-Requiring Microorganism and Mammalian B₁₂-Binding Protein

	relative B ₁₂ activity (% against the activity of CN-B ₁₂)			
	CN-B ₁₂	pseudo-B ₁₂	spirulina compound I	spirulina compound II
<i>L. leichmannii</i>	100	96.1	98.1	98.2
intrinsic factor	100	36.1	32.1	98.5

^a The B₁₂ concentrations of the purified spirulina B₁₂ analogues, CN-B₁₂, and pseudo-B₁₂ (identical amount; 10 ng/mL) were assayed by both *L. leichmannii* bioassay and IF chemiluminescence methods. The experiment was performed in triplicate. The relative B₁₂ activity was defined as relative amount (percent) of the purified spirulina B₁₂ analogues and pseudo-B₁₂ against that of CN-B₁₂ determined with both methods.

**Figure 4.** Structures of the purified compounds I and II from spirulina tablets.

(1982) and our results in Figures 1 and 2 indicate that the spirulina tablets contain substantial amounts of various B₁₂ substitutive compounds and/or inactive B₁₂ analogues (both cobinamide-like and/or -dislike compounds) and a small amount of B₁₂ analogues active in the binding to IF. The two IF-active B₁₂ analogues [major compound I (~83%) and minor compound II (~17%)] were isolated from spirulina tablets and identified as pseudo-B₁₂ and B₁₂, respectively (Figure 4), indicating that pseudo-B₁₂ is the predominate cobamide in spirulina tablets.

Various anaerobic bacteria can synthesize substantial amounts (600–670 nmol/g of dry cells) of pseudo-B₁₂ de novo (Stupperich et al., 1990). Some green algae can take up and then accumulate exogenous B₁₂, which is not essential for cell growth (Watanabe et al., 1991, 1997). It is not, however, clear whether *Spirulina* cells have the ability to synthesize pseudo-B₁₂ de novo or to take up the exogenous one (or both).

Several studies have shown that spirulina B₁₂ may not be bioavailable in mammals (Dagnelie et al., 1991; Herbert and Drivas, 1982; van den Berg et al., 1988). IF involved in the intestinal absorption of B₁₂ (Kolhouse and Allen, 1977) strictly recognizes the structure of the B₁₂ molecule. Pseudo-B₁₂ has been reported to reveal moderate affinity to IF among various B₁₂ analogues (Stupperich and Nexø, 1991). Intestinal absorption and ileal content of pseudo-B₁₂ 24 h after oral administration of radiolabeled pseudo-B₁₂ to rabbits have been shown to be ~13–21% of those of authentic B₁₂ (Kolhouse and Allen, 1977). An intravenous injection of transcobalamin II–pseudo-B₁₂ complex has shown that plasma clearance and tissue distribution of pseudo-B₁₂ are very similar to those of authentic B₁₂ but that urinary corrinoid excretion is slightly greater in the pseudo-B₁₂-injected rabbits than in the authentic B₁₂-injected rabbits (Kolhouse and Allen, 1977). Although the adenosyl coenzyme form of pseudo-B₁₂ has a 1000-

fold higher *K_m* for adenosyl-B₁₂-dependent mammalian methylmalonyl-CoA mutase than does adenosyl-B₁₂ (Lengyel et al., 1960), pseudo-B₁₂ can be fully active in human methyl-B₁₂-dependent apomethionine synthase under the experimental conditions used by Kolhouse et al. (1991). These observations suggest that pseudo-B₁₂ does not have the ability to act as a B₁₂ antagonist in mammals. Herbert (1988) has reported that an extract of spirulina contains two B₁₂ analogues which can block B₁₂ metabolism. We could not find another B₁₂-like compound capable of binding to IF in the extract of spirulina tablets. The B₁₂ analogues inactive for the binding of IF would be hardly absorbed in mammalian intestine by the IF-mediated system. van den Berg et al. (1991) have demonstrated that a spirulina-supplemented diet does not induce in rats a severe B₁₂ deficiency, implying that feeding of spirulina may not interfere with B₁₂ metabolism. To clarify the B₁₂ analogues and/or other compounds that have the ability to block B₁₂ metabolism, further biochemical studies are needed.

The results presented here strongly suggest that spirulina tablet algal health food is not suitable for use as a B₁₂ source, especially in vegetarians.

ACKNOWLEDGMENT

We thank Dr. K. Sato, Hiroshima University, Japan, for a kind gift of *L. leichmannii* ATCC7830 and Miss M. Itoi, Miss S. Nakata, and Miss M. Ichimori for technical assistance.

LITERATURE CITED

- Dagnelie, P. C.; van Staveren, W. A.; van den Berg, H. Vitamin B₁₂ from algae appears not to be bioavailable. *Am. J. Clin. Nutr.* **1991**, *53*, 695–697.
- Frenkel, E. P.; Prough, R.; Kitchens, R. L. Measurement of tissue vitamin B₁₂ by radioisotopic competitive inhibition assay and quantitation of tissue cobalamin fractions. *Methods Enzymol.* **1980**, *67*, 31–40.
- Hayashi, K.; Hayashi, T.; Kojima, I. A natural sulfated polysaccharide, calcium spirulan, isolated from *Spirulina plantensis*: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. *AIDS Res. Hum. Retroviruses* **1996**, *12*, 1463–1471.
- Herbert, V. Vitamin B₁₂: plant sources, requirements, and assay. *Am. J. Clin. Nutr.* **1988**, *48*, 852–858.
- Herbert, V.; Drivas, G. Spirulina and vitamin B₁₂. *JAMA—J. Am. Med. Assoc.* **1982**, *248*, 3096–3097.
- Kolhouse, J. F.; Allen, R. H. Absorption, plasma transport, and cellular retention of cobalamin analogues in the rabbit. *J. Clin. Invest.* **1977**, *60*, 1381–1392.
- Kolhouse, J. F.; Utley, C.; Stabler, S. P.; Allen, R. H. Mechanism of conversion of human apo- to homomethionine synthase by various forms of cobalamin. *J. Biol. Chem.* **1991**, *266*, 23010–23015.
- Lengyel, P.; Masumder, R.; Ochoa, S. Mammalian methylmalonyl isomerase and vitamin B₁₂ coenzymes. *Proc. Natl. Acad. Sci. U.S.A.* **1960**, *46*, 1312–1318.
- Schneider, Z. The occurrence and distribution of corrinoids. In *Comprehensive B₁₂*; Schneider, Z., Stroiński, A., Eds.; de Gruyter: Berlin, Germany, 1987; pp 157–223.
- Stupperich, E.; Kräutler, B. Pseudovitamin B₁₂ or 5-hydroxybenzimidazolyl-cobamide are the corrinoids found in methanogenic bacteria. *Arch. Microbiol.* **1988**, *148*, 268–271.
- Stupperich, E.; Nexø, E. Effect of the cobalt-N coordination on the cobamide recognition by the human vitamin B₁₂ binding proteins intrinsic factor, transcobalamin, and haptocorrin. *Eur. J. Biochem.* **1991**, *199*, 299–303.

- Stupperich, E.; Eisinger, H. J.; Schurr, S. Corrinoids in anaerobic bacteria. *FEMS Microbiol. Rev.* **1990**, *87*, 355–360.
- Vadiraja, B. B.; Gaikwad, N. W.; Madyastha, K. M. Hepatoprotective effect of C-phycoerythrin: protection for carbon tetrachloride and *R*-(+)-pulegone-mediated hepatotoxicity in rats. *Biochem. Biophys. Res. Commun.* **1998**, *249*, 428–431.
- van den Berg, H.; Dagnelie, P. C.; van Staveren, W. A. Vitamin B₁₂ and seaweed. *Lancet* **1988**, *1*, 242–243.
- van den Berg, H.; Brandsen, L.; Sinkeldam, B. J. Vitamin B₁₂ content and bioavailability of spirulina and nori in rats. *J. Nutr. Biochem.* **1991**, *2*, 314–318.
- Watanabe, F.; Nakano, Y.; Tamura, Y.; Yamanaka, H. Vitamin B₁₂ metabolism in a photosynthesizing green alga, *Chlamydomonas reinhardtii*. *Biochim. Biophys. Acta* **1991**, *1075*, 36–41.
- Watanabe, F.; Abe, K.; Takenaka, S.; Tamura, Y.; Maruyama, I.; Nakano, Y. Occurrence of cobalamin coenzymes in the photosynthetic green alga, *Chlorella vulgaris*. *Biosci., Biotechnol., Biochem.* **1997**, *61*, 896–897.
- Watanabe, F.; Takenaka, S.; Abe, K.; Tamura, Y.; Nakano, Y. Comparison of a microbiological assay and fully automated chemiluminescent system for the determination of vitamin B₁₂ in foods. *J. Agric. Food Chem.* **1998**, *46*, 1433–1436.
- Yang, H. N.; Lee, E. H.; Kim, H. M. *Spirulina platensis* inhibits anaphylactic reaction. *Life Sci.* **1997**, *61*, 1237–1244.

Received for review May 19, 1999. Revised manuscript received August 9, 1999. Accepted August 23, 1999. This study was supported in part by research funds of Kochi Women's University (F.W., H.K., and K.A.) and the Japanese Private School Foundation (F.W., S.T., and Y.T.).

JF990541B